Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222371 | 0.78 | HPGD (0.66) | BRD4HPGDALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL22193270 | 0.78 | LTA4H (0.48) | GLAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL10853040 | 0.77 | ALDH1A1 (0.49) | GLAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4143101 | 0.77 | ALDH1A1 (0.59) | GLAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL306069 | 0.76 | ALDH1A1 (0.54) | GLAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL30492998 | 0.76 | ALDH1A1 (0.54) | GLAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL12345122 | 0.75 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL23426349 | 0.74 | NAMPT (0.50) | GLAHPGDALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL305021 | 0.74 | ALDH1A1 (0.56) | GLAHPGDALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL20234917 | 0.74 | CYP2C19 (0.53) | GLAALDH1A1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | GRIN2B, GRIN3B, GRIN3A | BRD4 449/4885GLA 3231/4885HPGD 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.